NASDAQ:DARE

Daré Bioscience Stock Earnings Reports

etoro logo Buy DARE
*Your capital is at risk
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026

Daré Bioscience Earnings Calls

Mar 31, 2026
-$0.200 (39.39%)
Release date May 14, 2026
EPS estimate -$0.330
EPS actual -$0.200
EPS Surprise 39.39%
Revenue estimate 27K
Revenue actual 152.455K
Revenue Surprise 464.65%
Dec 31, 2025
-$0.0200 (91.67%)
Release date Mar 26, 2026
EPS estimate -$0.240
EPS actual -$0.0200
EPS Surprise 91.67%
Revenue estimate 751.5K
Revenue actual 1.024M
Revenue Surprise 36.22%
Sep 30, 2025
-$0.280 (15.15%)
Release date Nov 13, 2025
EPS estimate -$0.330
EPS actual -$0.280
EPS Surprise 15.15%
Revenue estimate 765K
Revenue actual 2.262K
Revenue Surprise -99.70%
Jun 30, 2025
-$0.450 (18.18%)
Release date Aug 14, 2025
EPS estimate -$0.550
EPS actual -$0.450
EPS Surprise 18.18%
Revenue estimate 147.25K
Revenue actual -21172
Revenue Surprise -114.38%

Last 4 Quarters for Daré Bioscience

Below you can see how DARE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025 Beat
Release date Aug 14, 2025
Price on release $2.07
EPS estimate -$0.550
EPS actual -$0.450
EPS surprise 18.18%
Date Price
Aug 08, 2025 $1.92
Aug 11, 2025 $1.97
Aug 12, 2025 $2.03
Aug 13, 2025 $2.11
Aug 14, 2025 $2.07
Aug 15, 2025 $2.20
Aug 18, 2025 $2.11
Aug 19, 2025 $2.02
Aug 20, 2025 $2.06
4 days before 7.81%
4 days after -0.483%
On release day 6.28%
Change in period 7.29%
Sep 30, 2025 Beat
Release date Nov 13, 2025
Price on release $1.89
EPS estimate -$0.330
EPS actual -$0.280
EPS surprise 15.15%
Date Price
Nov 07, 2025 $1.83
Nov 10, 2025 $1.82
Nov 11, 2025 $1.94
Nov 12, 2025 $1.98
Nov 13, 2025 $1.89
Nov 14, 2025 $1.90
Nov 17, 2025 $1.81
Nov 18, 2025 $1.78
Nov 19, 2025 $1.71
4 days before 3.28%
4 days after -9.52%
On release day 0.529%
Change in period -6.56%
Dec 31, 2025 Beat
Release date Mar 26, 2026
Price on release $1.51
EPS estimate -$0.240
EPS actual -$0.0200
EPS surprise 91.67%
Date Price
Mar 20, 2026 $1.36
Mar 23, 2026 $1.37
Mar 24, 2026 $1.36
Mar 25, 2026 $1.40
Mar 26, 2026 $1.51
Mar 27, 2026 $1.55
Mar 30, 2026 $1.83
Mar 31, 2026 $1.82
Apr 01, 2026 $1.90
4 days before 11.03%
4 days after 25.83%
On release day 2.65%
Change in period 39.71%
Mar 31, 2026 Beat
Release date May 14, 2026
Price on release $2.86
EPS estimate -$0.330
EPS actual -$0.200
EPS surprise 39.39%
Date Price
May 08, 2026 $2.75
May 11, 2026 $2.52
May 12, 2026 $2.63
May 13, 2026 $2.84
May 14, 2026 $2.86
May 15, 2026 $2.17
May 18, 2026 $2.11
May 19, 2026 $2.25
May 20, 2026 $2.33
4 days before 4.00%
4 days after -18.53%
On release day -24.13%
Change in period -15.27%

Daré Bioscience Earnings Call Transcript Summary of Q1 2026

Dare Bioscience is executing a dual-path commercialization strategy: (1) make proprietary formulations available immediately via 503B compounding (telehealth + specialty pharmacy channels) while (2) pursue FDA approval (505(b)(2) NDAs) for select assets. Key near-term commercial milestones: Flora Sync LF5 (vaginal probiotic) launches commercially in June 2026 and is expected to generate the company’s first direct product revenue; DARE to PLAY (sildenafil topical arousal cream) is available for pre-fulfillment nationwide and the company expects 503B dispensing to begin this summer with product revenue for DARE to PLAY targeted in Q3 2026. Clinical pipeline highlights: Ovaprene (hormone-free monthly intravaginal contraceptive) had a second consecutive positive DSMB review in its Phase III trial, with enrollment on track to reach at least 2,500 cycles of exposure in 2026 and primary endpoint analysis targeted in 2027; DARE-HPV advanced to IND-cleared status and is moving into a Phase II study supported by ARPA-H funding; other grant-funded programs (DARE-LARC1, Casea S, DARE-NHC, DARE-PTB1) continue to progress. Financial position: cash and equivalents totaled approximately $18.5M at quarter end, working capital was roughly $0.5M, and the company continues to rely meaningfully on nondilutive grant funding (Gates Foundation, ARPA-H, NIH). Management notes that without projected revenue they do not currently have a full 12-month runway and will monitor financing needs; product revenue is expected to supplement grants and financings as a third capital leg. Commercial strategy emphasizes clinician adoption and real-world data generation via the 503B channel to support future NDA filings and partnerships.

Daré Bioscience Earnings History

Earnings Calendar

FAQ

When is the earnings report for DARE?
Daré Bioscience, Inc. (DARE) has scheduled its earnings report for Aug 13, 2026 after the markets close.

What is the DARE price-to-earnings (P/E) ratio?
DARE P/E ratio as of Jun 03, 2026 (TTM) is -2.48.

What is the DARE EPS forecast?
The forecasted EPS (Earnings Per Share) for Daré Bioscience, Inc. (DARE) for the first fiscal quarter 2026 is -$0.330.

What are Daré Bioscience, Inc.'s retained earnings?
On its balance sheet, Daré Bioscience, Inc. reported retained earnings of $152.46 thousand for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE